CN109627182B - Hydroxyl benzene salicylamine hydroxylate, preparation method and application thereof - Google Patents
Hydroxyl benzene salicylamine hydroxylate, preparation method and application thereof Download PDFInfo
- Publication number
- CN109627182B CN109627182B CN201810660090.5A CN201810660090A CN109627182B CN 109627182 B CN109627182 B CN 109627182B CN 201810660090 A CN201810660090 A CN 201810660090A CN 109627182 B CN109627182 B CN 109627182B
- Authority
- CN
- China
- Prior art keywords
- hydroxylate
- salicylamine
- reaction
- hydroxyl
- hepatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 Hydroxyl benzene salicylamine Chemical compound 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 17
- 229940079593 drug Drugs 0.000 claims abstract description 12
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 12
- 230000010076 replication Effects 0.000 claims abstract description 7
- 241000700721 Hepatitis B virus Species 0.000 claims abstract description 6
- 108010041388 Ribonucleotide Reductases Proteins 0.000 claims description 14
- 102000000505 Ribonucleotide Reductases Human genes 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 abstract description 5
- 108090000790 Enzymes Proteins 0.000 abstract description 5
- 238000006243 chemical reaction Methods 0.000 description 42
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 39
- 150000001875 compounds Chemical class 0.000 description 19
- 239000000543 intermediate Substances 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 208000002672 hepatitis B Diseases 0.000 description 10
- OVVRATJIZPFMQS-UHFFFAOYSA-N 2-[(n-hydroxyanilino)methyl]phenol Chemical compound C=1C=CC=CC=1N(O)CC1=CC=CC=C1O OVVRATJIZPFMQS-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical group CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 229940126062 Compound A Drugs 0.000 description 8
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 8
- 238000003032 molecular docking Methods 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 201000007270 liver cancer Diseases 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 208000006454 hepatitis Diseases 0.000 description 6
- 231100000283 hepatitis Toxicity 0.000 description 6
- 208000014018 liver neoplasm Diseases 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- LGCMKPRGGJRYGM-UHFFFAOYSA-N Osalmid Chemical compound C1=CC(O)=CC=C1NC(=O)C1=CC=CC=C1O LGCMKPRGGJRYGM-UHFFFAOYSA-N 0.000 description 5
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 230000004543 DNA replication Effects 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 239000006227 byproduct Substances 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 4
- 150000007530 organic bases Chemical class 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- UGFGDRANRAQQKT-UHFFFAOYSA-N 2-hydroxy-n-(2-hydroxyphenyl)benzamide Chemical group OC1=CC=CC=C1NC(=O)C1=CC=CC=C1O UGFGDRANRAQQKT-UHFFFAOYSA-N 0.000 description 3
- 108091036055 CccDNA Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 101000575639 Homo sapiens Ribonucleoside-diphosphate reductase subunit M2 Proteins 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- 102100026006 Ribonucleoside-diphosphate reductase subunit M2 Human genes 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- GLOUAZQXRGOKNV-UHFFFAOYSA-N 2-hydroxybenzamide;phenol Chemical compound OC1=CC=CC=C1.NC(=O)C1=CC=CC=C1O GLOUAZQXRGOKNV-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108020004638 Circular DNA Proteins 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- 102000005945 Regulatory Factor X1 Human genes 0.000 description 2
- 108010030933 Regulatory Factor X1 Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 2
- 229960001627 lamivudine Drugs 0.000 description 2
- 238000002514 liquid chromatography mass spectrum Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012454 non-polar solvent Substances 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 229950011258 osalmid Drugs 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 239000001358 L(+)-tartaric acid Substances 0.000 description 1
- 206010053961 Mitochondrial toxicity Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 229910021627 Tin(IV) chloride Inorganic materials 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 231100000296 mitochondrial toxicity Toxicity 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- 230000009220 viral host cell interaction Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Landscapes
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a hydroxyl benzene salicylamine hydroxylate which can inhibit the replication of hepatitis B virus DNA by inhibiting RR enzyme, and also discloses a preparation method of the hydroxyl benzene salicylamine hydroxylate, which is helpful for solving the technical problem that the existing drug molecules with the inhibiting effect on RR enzyme are still rare.
Description
Technical Field
The invention relates to hydroxyl benzene salicylamine hydroxylate, which has the following structural formula:
the invention also relates to the preparation and application of the hydroxyl benzene salicylamine hydroxylate.
Background
Viral hepatitis B (hepatitis B) is still one of important infectious diseases seriously threatening the health of people in China, and is a main factor causing primary liver cancer in China. The HBsAg carrying rate of people in China is nearly 7.2%, and about 3.5 hundred million people all over the world suffer from HBV infection. The existing research shows that the inhibition of HBV DNA replication can prevent the progress of hepatitis B disease, slow down and even reverse liver fibrosis and cirrhosis and reduce the incidence rate of liver cancer. The nucleotide analogue treatment recommended by the current international anti-HBV treatment guidelines still has more adverse reactions and higher drug resistance rate and virus variation defects. In addition, the existing drugs can not completely eliminate cccDNA (divalently closed circular dna) in the liver cell nucleus of hepatitis b patients, and the continuous existence of cccDNA in patients is a main reason that chronic HBV infection is difficult to cure, and in fact, HBV variation and drug resistance caused by nucleoside (acid) analogues are difficult problems in the global hepatitis b treatment history and are also important obstacles for overcoming hepatitis b.
At present, researches suggest that the drug resistance incidence rate of drugs taking proteins in host cells as targets is obviously reduced compared with drugs directly acting on viruses, and mitochondrial toxicity of nucleoside (acid) analogues can be avoided by taking the proteins in the host cells as drug targets. Therefore, the search of virus-host cell interaction sites as new antiviral targets in the HBV replication cycle, so as to develop a new anti-HBV treatment scheme capable of clearing cccDNA and reducing the incidence of drug resistance, is a key problem to be solved urgently in the treatment of hepatitis B and the prevention and treatment of hepatitis B-related liver cancer at present, and has important clinical and social meanings.
Ribonucleotide Reductase (RR) is a key enzyme in the synthesis and repair of human cellular DNA, and functions to reduce ribonucleotides (NDPs) to deoxyribonucleotides (dNDPs), which are further phosphorylated to dNTPs by kinases to provide starting materials for DNA synthesis. HBV has no gene for encoding RR enzyme, most normal liver cells in the liver of adults are in a static state, and the concentration of dNTPs is very low. HBV (No RR gene) inhibits the combination of hepatocyte regulatory factor x1(RFX1) and the promoter of RRM2 or activates Chk1-E2F1 pathway of DNA damage pathway through HBx protein so as to activate the RR enzyme expression and enzyme activity of host hepatocytes, and the abnormally activated RR enzyme can provide sufficient DNA synthesis raw materials and ensure the replication of HBV and the demand of liver cancer cells on DNA raw materials, so that the RR enzyme is a key factor protein for the occurrence and development of hepatitis B and related liver cancer and is a new target molecule of anti-hepatitis B drugs. The RR enzyme inhibitor can cut off the supply of HBV DNA replication raw materials, inhibit the synthesis of double-stranded relaxed circular molecule RcDNArcDNA (strained circular DNA), prevent the replication of a large amount of HBV in liver cells, and is expected to effectively inhibit the formation of HBVcccDNA from the source, thereby relieving inflammatory injury of liver tissues, preventing the generation and development of hepatitis and converting the hepatitis into liver cancer.
Disclosure of Invention
Although RR enzyme is found to be a key factor protein for the occurrence and development of hepatitis B and related liver cancer at present, drug molecules with an inhibitory effect on RR enzyme are still rare, and the invention provides a drug molecule with an inhibitory effect on RR enzyme, wherein the molecule is hydroxyl-phenyl salicylamide hydroxylate, and the structural formula of the molecule is as follows:
the invention discovers that analysis of the molecule by using molecular docking software eHiTS (Version 12.0, SimBioSys Inc., Canada) of SimBioSys company shows that the eHiTS _ Score value (log (Kd) corresponding to eHiTS _ Score (logarithm of dissociation constant) is higher, and the more negative value represents that the binding capacity of the small molecular compound is stronger, such as-6 is equivalent to mu M, -9 is equivalent to nM, the numerical difference is 1, and the binding capacity is 10 times different), is-3.807.
In addition, the hydroxyl phenyl salicylamine hydroxylate also has a very strong function of inhibiting the replication of hepatitis B virus DNA, so that the hydroxyl phenyl salicylamine hydroxylate (C4) can be used for preparing a medicament for treating hepatitis B, and particularly, the hydroxyl phenyl salicylamine hydroxylate (C4) is used for preparing a medicament for preventing and treating hepatitis (especially hepatitis B).
The medicament can be prepared into dosage forms suitable for various administration forms.
The invention also provides a method for preparing hydroxyl benzene salicylamine hydroxylate, which comprises the following steps:
a. a step of dissolving the intermediate and adding a catalyst to form a first mixture;
b. the first mixture is hydrogenated and completely reacted to generate hydroxyl benzene salicylamine hydroxylate;
the catalyst is one of palladium carbon, raney nickel, stannic chloride and ferric trichloride, and the intermediate is as follows:
the reaction yield of the step b can reach more than 80 percent. And (b) dissolving the intermediate in the step a, and adding a catalyst, wherein the solvent selected in the step a can dissolve the intermediate, and is generally dichloromethane, methanol, ethanol, tert-butyl alcohol, acetonitrile, tetrahydrofuran and dioxane, preferably methanol.
Various specifications for the catalyst may be used for the hydrogenation of the intermediate, palladium on carbon being generally preferred for the catalyst. The reaction temperature of the step b is controlled to be 0-50 ℃.
The intermediate can be synthesized by one skilled in the art using various synthetic routes, but in the present invention, the intermediate is generated by reacting compound a:
the compound B is:
wherein X is Cl, Br or I.
For compound a and compound B, the synthesis can be performed by the skilled person in the art by looking up the technical documentation, and the invention is not described further.
The synthesis steps of the intermediate comprise:
c. mixing and dissolving the compound A and the compound B to form a second mixture;
d. and (4) completely reacting the second mixture to generate an intermediate.
The reaction yield of the step d can reach more than 70 percent, and the solvent selected in the step c is a nonpolar solvent, and polar solvents such as alcohols and the like cannot be used. The nonpolar solvent can be at least one of dichloromethane, dichloroethane, tetrahydrofuran, acetonitrile and dioxane, preferably dichloromethane and tetrahydrofuran.
The c step further comprises the step of cooling the second mixture during the mixing of compound a and compound B to form the second mixture to inhibit the formation of by-products. In some embodiments of the invention, the step of cooling the second mixture is capable of maintaining the temperature of the second mixture at-15 ℃ to 35 ℃, preferably-15 ℃ to 15 ℃.
In order to ensure that the compound A and the compound B can smoothly react, the step c further comprises the step of adding a hydrogen-free organic base to the second mixture, and in the step, the second mixture is still cooled, so that the temperature of the second mixture added with the organic base is controlled below 15 ℃, so as to keep the reaction efficiency and simultaneously reduce the generation of byproducts as much as possible. In some embodiments of the invention, the organic base is triethylamine, N-diisopropylethylamine, pyridine, 4-dimethylaminopyridine, preferably triethylamine.
Generally, the molar charge ratio of the compound A, the compound B and the organic base is 1:1-3:1-3, preferably 1:1-2: 1-2.
Theoretically, a person skilled in the art can synthesize the hydroxyphenyl salicylamide hydroxylate by adopting other synthetic routes, but the synthetic method provided by the invention has obvious technical effects:
1. the raw materials are cheap, the cost is low, the purchase is very convenient, the raw materials for synthesizing the compound A and the compound B can be selected as the initial raw materials by technical personnel according to technical documents.
2. The reaction in the step b and the step d is sufficient, byproducts are not easy to generate, and in fact, the reaction yield in the step b and the step d is more than 70%.
3. The obtained byproducts have certain water solubility, and the intermediate and the hydroxyl-phenyl salicylamine hydroxylate can be purified by simple water washing and extraction, so that the purification cost is reduced.
Drawings
FIG. 1 is a LC/MS spectrum of the intermediate of example 1;
FIG. 2 is a nuclear magnetic spectrum of hydroxyl-phenyl salicylamine hydroxylate in example 5;
FIG. 3 is a LC/MS spectrum of hydroxyl-phenyl salicylamide hydroxylate of example 5;
FIG. 4 is an HPLC chromatogram of hydroxyl-phenyl salicylamide hydroxylate of example 5;
fig. 5 is a structural diagram of the RRM23D according to embodiment 10;
FIG. 6 is a graph showing the effect of each drug on HBV DNA as described in example 11.
Detailed Description
The following describes the implementation of the present invention in further detail with reference to the accompanying drawings.
A. Preparation process of hydroxyphenyl salicylamine hydroxylate
In this section, compound B is
1. For the preparation of intermediates
Example 1
At room temperature, adding dichloromethane (20L) into a reaction kettle, sequentially adding a compound A (5.00kg, 16.37mol, 1.0eq) and a compound B (8.08kg, 32.75mol, 2.0eq) into the reaction kettle, cooling to 0-5 ℃, dropwise adding a dichloromethane solution of 4-dimethylaminopyridine (4.00kg, 32.75mol, 2.0eq), after dropwise adding, keeping the temperature for reaction for 1h, controlling the reaction to be complete, adding water (10L) into the reaction solution, extracting with dichloromethane, directly concentrating to obtain 7.85kg of yellow oily matter, wherein the molar yield is 93%, and the obtained product is directly used in the next step without purification.
EI-MS [ M +1] ═ 516.3, see fig. 1.
Example 2
Adding tetrahydrofuran (400mL) into a reaction kettle at room temperature, sequentially adding a compound A (100.00g, 0.33mol, 1.0eq) and a compound B (162.81g, 0.66mol, 2.0eq) into the reaction kettle, cooling to 0-5 ℃, dropwise adding a dichloromethane solution of triethylamine (66.66g, 0.66mol, 2.0eq), after dropwise adding, keeping the temperature for reaction for 2 hours, controlling the reaction to be complete, adding water (200mL) into the reaction solution, concentrating, extracting with dichloromethane, and concentrating again to obtain 147.91g of yellow oily matter, wherein the molar yield is 87.6%, and the obtained product is directly used in the next step without purification.
Example 3
At room temperature, adding acetonitrile (400mL) into a reaction kettle, sequentially adding a compound A (100.00g, 0.33mol, 1.0eq) and a compound B (162.81g, 0.66mol, 2.0eq) into the reaction kettle, cooling to 0-5 ℃, dropwise adding a dichloromethane solution of N, N-diisopropylethylamine (128.0g, 0.99mol, 3.0eq), after dropwise adding, carrying out heat preservation reaction for 2 hours, controlling the reaction to be complete, adding water (200mL) into a reaction solution, concentrating, extracting with dichloromethane, and concentrating again to obtain 151.77g of yellow oily matter, wherein the molar yield is 89.2%, and the obtained product is directly used in the next step without purification.
Example 4
At room temperature, adding dichloromethane (1200mL) into a reaction kettle, sequentially adding a compound A (100.00g, 0.33mol, 1.0eq) and a compound B (162.81g, 0.66mol, 3.0eq) into the reaction kettle, cooling to 0-5 ℃, dropwise adding a dichloromethane solution of 4-dimethylaminopyridine (120.95g, 0.99mol, 3.0eq), after dropwise adding, keeping the temperature for reaction for 2 hours, controlling the reaction to be complete, adding water (200mL) into the reaction liquid, extracting with dichloromethane, and concentrating again to obtain 148.35g of yellow oily matter, wherein the molar yield is 87.2%, and the obtained product is directly used in the next step without purification.
2. Preparation of hydroxyl benzene salicylamine hydroxylate
Example 5
Methanol (100L) is added into a reaction kettle at room temperature, then the intermediate obtained in the examples 1-4 (7.85kg, 15.22mol, 1.0eq) and palladium carbon (785g, 10%) are sequentially added, hydrogen is filled into the reaction kettle, the pressure of 0.2MPa is maintained, the reaction is carried out for 10 hours at room temperature, after the reaction is finished, the reaction product is filtered, the filtrate is concentrated to be dry, and 3.20kg of pink solid is obtained, and the molar yield is 85.6%.
The nuclear magnetic spectrum is shown in FIG. 2.
EI-MS [ M +1] ═ 246.3, see fig. 3.
HPLC of hydroxyl phenyl salicylamine hydroxylate is shown in FIG. 4.
Example 6
Tetrahydrofuran (800mL) was added to the reaction vessel at room temperature, followed by the sequential addition of the intermediates (100g, 0.19mol, 1.0eq) obtained in examples 1-4, raney nickel (5g, 5%), followed by hydrogen, maintaining a pressure of 0.2MPa, reaction at 50 ℃ for 24h, after completion of the reaction, filtration, and concentration of the filtrate to dryness to obtain 38.67g of a pink solid with a molar yield of 81.3%.
Example 7
Methanol (1L) is added into a reaction kettle at room temperature, then the intermediate (100g, 0.19mol, 1.0eq) obtained in the example 1-4 and palladium carbon (10g, 10%) are sequentially added, hydrogen is filled in, the pressure of 0.2MPa is kept, the reaction is carried out for 5h at room temperature, after the reaction is finished, the filtration is carried out, the filtrate is concentrated to be dry, 39.14g of pink solid is obtained, and the molar yield is 82.3%.
Example 8
At room temperature, tert-butanol (300mL) was added to the reaction kettle, followed by the sequential addition of the intermediate obtained in examples 1-4 (100g, 0.19mol, 1.0eq), palladium on carbon (1g, 1%), hydrogen was charged, the pressure was maintained at 0.2MPa, the reaction was carried out at room temperature for 10h, after completion of the reaction, filtration was carried out, and the filtrate was concentrated to dryness to obtain 36.48g of a pink solid with a molar yield of 78.3%.
Example 9
Methanol (1L) is added into a reaction kettle at room temperature, then the intermediate (100g, 0.19mol, 1.0eq) obtained in the example 1-4 and palladium carbon (10g, 10%) are sequentially added, hydrogen is filled in, the pressure of 0.2MPa is kept, the reaction is carried out for 5h at room temperature, after the reaction is finished, the filtration is carried out, the filtrate is concentrated to be dry, 39.14g of pink solid is obtained, and the molar yield is 82.3%.
B. The function of hydroxyl-benzene salicylamide hydroxylate in inhibiting RR enzyme and hepatitis B virus DNA replication
1. Function of hydroxyl benzene salicylamine hydroxylate in inhibiting RR enzyme
Example 10
Molecular docking calculation of hydroxyphenyl salicylamine and derivatives thereof
(1) The magnitude of the binding capacity of 4 compounds to the target RRM2 was predicted by the molecular docking software eHiTS of SimBioSys corporation (Version 12.0, SimBioSys inc.
The 4 compounds are:
(2) molecular docking method
Preparation of small molecules: the 2D small molecules were converted to 3D structures using OpenBabel 2.3.0 for molecular docking studies.
Target and active pocket definitions: the crystal structure of RRM2 was obtained from the PDB library (PDB code:3OLJ), and the definition of its active pocket was described in Xia Liu et al, Biochemical Pharmacology, i.e., the region where F244, D271, R330 and E334 are located, is defined as the active site.
The molecular docking method comprises the following steps: molecular docking studies were performed using eHiTS software from Wiley. eHiTS is a precise and rapid flexible molecular docking software. The ehITS can automatically preprocess the target; and the butted small molecules only need to be in a 3D structure and do not need to be in the lowest-energy conformation. The accuracy parameter during docking, accuracracy, is set to 6, i.e., the highest accuracy molecular docking is performed. Oxybenzsalicylamide and its derivatives were separately tethered to this site to evaluate their ability to bind RRM 2.
(3) Scoring the binding Capacity of the Compounds
The docking scores of the 4 small molecules are as follows, and the sequencing is carried out according to the strength of the binding capacity:
| Name | eHiTS-Score |
| OH-1.mol | -3.807 |
| Osalmid.mol | -2.885 |
| OH-2.mol | -2.424 |
| HU.mol | -2.289 |
note: the eHiTS software evaluates the amount of binding ability of small molecule compounds to targets by eHiTS _ Score. eHiTS _ Score corresponds to log (kd) (log of dissociation constant), more negative values indicate stronger binding of small molecule compounds, e.g., -6 for μ M, -9 for nM; the difference in the values was 1, and the binding capacity was 10-fold.
2. Function of hydroxyl benzene salicylamine hydroxylate in inhibiting hepatitis B virus DNA replication
Example 11
Experiment on anti-HBV activity of hydroxyl benzene salicylamine hydroxylate in vitro.
1. Experimental Material
(1) Cell lines: HepG 2.2.15 cells (stably transfected HBV gene, HBV genome replication and expression can be stably carried out, and the cells are preserved in the laboratory.
(2) The main reagents are as follows: hydroxyphenyl salicylamide hydroxylate (OH-1, Hangzhou nuclide chemical technologies, Ltd.), hydroxyphenyl salicylamide (Osalmid, Beijing Bailingwei science and technology, Ltd.), lamivudine (3-TC, Beijing Bailingwei science and technology, Ltd.), hydroxyurea (HU, Beijing Bailingwei science and technology, Ltd.), and a hepatitis B virus nucleic acid quantitative determination kit (Hunan Shengxiang biotechnology, Ltd.)
(3) The main apparatus is as follows: carbon dioxide incubator (Thermo Forma corporation, USA), real-time fluorescence quantitative PCR instrument (ABI corporation, USA 7500Fast)
2. The experimental method comprises the following steps:
(1) cell culture:
HepG 2.2.15 and A64 cells were cultured in DMEM high-sugar medium (supplemented with 10% fetal bovine serum, 1% streptomycin, 400. mu.g/ml G418, 2mmol/L glutamine) and placed in a cell culture incubator at 37 ℃ with 5% CO2And (5) culturing under an environment. When the cells grow to 70-80%, the cells are digested and passaged by pancreatin containing EDTA.
(2) Determining the inhibitory effect of the drug on HBV DNA in the supernatant of HepG 2.2.15 cell culture:
compounding hydroxyl benzene salicylamide hydroxylate into HepG 2.2.15 cells with DMEM medium without G4184Laying 24-well plates at a density of one/mL, adding 500uL of cell suspension per well, and placing CO2After 24h of incubation at 37 ℃, the cells adhere to the wall and grow well, the culture solution is aspirated, and 500 mu L of culture medium containing medicine is added into each hole, wherein each concentration is 3 multiple holes. Collecting culture medium supernatant on the 4 th, 6 th and 8 th days of culture to detect HBV DNA content. Adding 5uL sample releasing agent into 5uL cell culture supernatant, mixing, and incubating at room temperature for 10After min, adding 38uL of reaction solution, 2uL of enzyme mixed solution and 0.2uL of internal standard, and carrying out amplification according to the following conditions: after pre-denaturation at 50 ℃ for 2min and 94 ℃ for 5min, the cycle is repeated for 40 cycles at 94 ℃ for 15s and 57 ℃ for 30s and signals are collected. And (3) automatically calculating the quantitative result of the HBV DNA by a ratio instrument of the Ct value of the standard product.
3. Statistical analysis:
the experimental data were processed with SPSS 13.0 software and the results were as follows
It is shown that the comparison of the mean of the multiple samples was analyzed using One-way ANOVA, and that p < 0.05 was statistically significantly different.
4. The experimental results are as follows:
compared with a blank group control group, the hydroxyl benzene salicylamine hydroxylate has obvious inhibitory effect (P is less than 0.01) on HBV copy number at the dose of 10uM on 4 th, 6 th and 8 th days after drug addition, and is enhanced along with the prolonging of the acting time. The inhibition effect is superior to that of the prototype hydroxyphenyl salicylamine and lower than that of lamivudine.
Table 1 effect of each drug on HepG 2.2.15 cell culture supernatant HBV DNA (n-3,
)
p < 0.01, P < 0.001, P < 0.0001 compared with control group
The above description is only an embodiment of the present invention, and is not intended to limit the design of the present invention, and all equivalent changes made according to the design key of the present invention fall within the protection scope of the present invention.
Claims (2)
1. The application of the hydroxyl benzene salicylamine hydroxylate in the preparation of drugs for inhibiting the activity of ribonucleotide reductase, wherein the structural formula of the hydroxyl benzene salicylamine hydroxylate is as follows:
2. the application of the hydroxyl benzene salicylamine hydroxylate in the preparation of the medicine for inhibiting the replication of hepatitis B virus DNA, wherein the structural formula of the hydroxyl benzene salicylamine hydroxylate is as follows:
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810660090.5A CN109627182B (en) | 2018-06-13 | 2018-06-13 | Hydroxyl benzene salicylamine hydroxylate, preparation method and application thereof |
| CN202110054359.7A CN112724037B (en) | 2018-06-13 | 2018-06-13 | Hydroxyl benzene salicylamine hydroxylate, preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810660090.5A CN109627182B (en) | 2018-06-13 | 2018-06-13 | Hydroxyl benzene salicylamine hydroxylate, preparation method and application thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110054359.7A Division CN112724037B (en) | 2018-06-13 | 2018-06-13 | Hydroxyl benzene salicylamine hydroxylate, preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109627182A CN109627182A (en) | 2019-04-16 |
| CN109627182B true CN109627182B (en) | 2021-04-02 |
Family
ID=66066259
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110054359.7A Active CN112724037B (en) | 2018-06-13 | 2018-06-13 | Hydroxyl benzene salicylamine hydroxylate, preparation method and application thereof |
| CN201810660090.5A Active CN109627182B (en) | 2018-06-13 | 2018-06-13 | Hydroxyl benzene salicylamine hydroxylate, preparation method and application thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110054359.7A Active CN112724037B (en) | 2018-06-13 | 2018-06-13 | Hydroxyl benzene salicylamine hydroxylate, preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN112724037B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117045680B (en) * | 2023-10-12 | 2023-12-08 | 北京国卫生物科技有限公司 | Stem cell preparation for promoting liver regeneration and preparation method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102920688A (en) * | 2011-11-16 | 2013-02-13 | 浙江大学 | Application of 4-hydroxy salicylanilide to preparation of medicament for preventing and treating hepatitis B |
| CN102379881B (en) * | 2011-11-16 | 2013-03-13 | 浙江大学 | Application of 4-hydroxy salicylamide in preparing medicament for resisting tumor |
| NZ708392A (en) * | 2012-12-06 | 2020-05-29 | Baruch S Blumberg Inst | Functionalized benzamide derivatives as antiviral agents against hbv infection |
-
2018
- 2018-06-13 CN CN202110054359.7A patent/CN112724037B/en active Active
- 2018-06-13 CN CN201810660090.5A patent/CN109627182B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN112724037B (en) | 2022-03-11 |
| CN109627182A (en) | 2019-04-16 |
| CN112724037A (en) | 2021-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2223921B1 (en) | 2-Thiophen-2-yl-oxazole, 2-Thiophen-2-yl-thiazole and 2-Thiophen-2-yl-1H-imidazole derivatives as antiviral agents | |
| CN1088758C (en) | Tag reagent and assay method | |
| Han et al. | Discovery of RG7834: the first-in-class selective and orally available small molecule hepatitis B virus expression inhibitor with novel mechanism of action | |
| Hosamani et al. | Microwave-assisted synthesis of new fluorinated coumarin–pyrimidine hybrids as potent anticancer agents, their DNA cleavage and X-ray crystal studies | |
| CN1950376A (en) | Curcumol derivatives, compositions comprising the same and use in manufacture of medicament | |
| EP2599784A1 (en) | Nucleotide and/or oligonucleotide and preparation process thereof | |
| Shi et al. | Antitumor agents. 172. Synthesis and biological evaluation of novel deacetamidothiocolchicin-7-ols and ester analogs as antitubulin agents | |
| CN109627182B (en) | Hydroxyl benzene salicylamine hydroxylate, preparation method and application thereof | |
| CN114957381A (en) | Novel deuterated cyano compound, preparation method, composition and application thereof | |
| Xi et al. | Targeting DNA bulged microenvironments with synthetic agents: lessons from a natural product | |
| KR20210119452A (en) | N-heterocyclic 5-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition and use thereof | |
| JP2010510965A5 (en) | ||
| WO2007133211A1 (en) | 3,4-disubstituted coumarin and quinolone compounds | |
| CN1419553A (en) | Prodigiosin-derivatives as neoplastic and anti-viral agents | |
| Tian et al. | Discovery of novel α-aminophosphonates with hydrazone as potential antiviral agents combined with active fragment and molecular docking | |
| CN108727442B (en) | Preparation method and application of salidroside glucuronic acid product | |
| Alhakamy et al. | Natural product-inspired synthesis of coumarin–chalcone hybrids as potential anti-breast cancer agents | |
| CN116987137A (en) | Capping compound and application thereof in mRNA capping | |
| Gulevich et al. | Multicomponent synthesis of artificial nucleases and their RNase and DNase activity | |
| CN109516926B (en) | Preparation and application of piperlonguminine derivative | |
| CN1198656C (en) | Dual action 2', 5'-oligoadenylate antiviral derivatives and uses thereof | |
| Jacobson et al. | Synthesis and conformation of a dinucleoside monophosphate modified by aniline | |
| Mohamed et al. | Revaluation of biomass-derived furfuryl alcohol derivatives for the synthesis of carbocyclic nucleoside phosphonate analogues | |
| Grabkowska-Drużyc et al. | Design, synthesis, antiviral, and cytostatic evaluation of novel isoxazolidine analogues of C-nucleotides | |
| Wang et al. | Design, synthesis and biological evaluation of caudatin analogs as potent hepatitis B virus inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |